Brentuximab Vedotina

Resumen

Alternativas con registro en Colombia

• Edrecolomab
• Gemtuzumab Ozogamicina
• Ipilimumab · costo anual estimado $ 1.144.599.485
• Blinatumomab · costo anual estimado $ 575.343.295
• Enfortumab Vedotina
• Polatuzumab Vedotin · costo anual estimado $ 634.694.850
• Sacituzumab Govitecan · costo anual estimado $ 835.929.935
• Tremelimumab
• Tarlatamab

Estudios clínicos principales

• A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial)
  Fase 3 · 2010 · 329 participantes · Seagen Inc. · NCT01100502 · PubMed 25796459
• A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma
  Fase 3 · 2012 · 1.334 participantes · Takeda · NCT01712490
• ECHELON-2: ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas
  Fase 3 · 2013 · 452 participantes · Seagen Inc. · NCT01777152
• ALCANZA: A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lympho
  Fase 3 · 2012 · 131 participantes · Millennium Pharmaceuticals, Inc. · NCT01578499

Enfermedades relacionadas

• Infecciones por hongos
• Trasplante (prevención del rechazo)
• Cáncer (todos)
• Linfomas

Fuentes

• Etiqueta FDA (DailyMed): ADCETRIS
• EMA: Adcetris